European principles of inhibitor management in patients with
haemophilia: implications of new treatment options

J 2020

European principles of inhibitor management in patients with haemophilia: implications of new treatment options

HERMANS, C., P. L. F. GIANGRANDE, B. O MAHONY, P. DE KLEIJN, M. BEDFORD et. al.

Basic information

Original name

European principles of inhibitor management in patients with haemophilia: implications of new treatment options

Authors

HERMANS, C. (56 Belgium), P. L. F. GIANGRANDE (56 Belgium), B. O MAHONY (56 Belgium), P. DE KLEIJN (528 Netherlands), M. BEDFORD (826 United Kingdom of Great Britain and Northern Ireland), A. BATOROVA (703 Slovakia), Jan BLATNÝ (203 Czech Republic, belonging to the institution) and K. JANSONE (56 Belgium)

Edition

Orphanet Journal of Rare Diseases, London, England, 2020, 1750-1172

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10603 Genetics and heredity

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.123

RIV identification code

RIV/00216224:14110/20:00116531

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1186/s13023-020-01511-8

UT WoS

000567119900003

Keywords in English

Haemophilia; Guidelines; Inhibitors; Factor VIII; Factor IX; Bypassing agents; Emicizumab; Immune tolerance

Abstract

V originále

In light of the rapidly changing landscape of haemophilia treatment, the authors of the position paper on the “European Principles of Inhibitor Management” published in 2018 (Table 1) now provide an update on the major impact of novel therapies that bypass and/or substitute clotting factor VIII (FVIII) and IX (FIX) in the care of haemophilia patients with FVIII- or FIXneutralizing allo-inhibitory antibodies (inhibitors).

Citovat

HERMANS, C., P. L. F. GIANGRANDE, B. O MAHONY, P. DE KLEIJN, M. BEDFORD, A. BATOROVA, Jan BLATNÝ and K. JANSONE. European principles of inhibitor management in patients with haemophilia: implications of new treatment options. Orphanet Journal of Rare Diseases. London: England, 2020, vol. 15, No 1, p. 1-4. ISSN 1750-1172. Available from: https://dx.doi.org/10.1186/s13023-020-01511-8.

@article{1681836,
   author = {Hermans, C. and Giangrande, P. L. F. and O Mahony, B. and de Kleijn, P. and Bedford, M. and Batorova, A. and Blatný, Jan and Jansone, K.},
   article_location = {London},
   article_number = {1},
   doi = {http://dx.doi.org/10.1186/s13023-020-01511-8},
   keywords = {Haemophilia; Guidelines; Inhibitors; Factor VIII; Factor IX; Bypassing agents; Emicizumab; Immune tolerance},
   language = {eng},
   issn = {1750-1172},
   journal = {Orphanet Journal of Rare Diseases},
   title = {European principles of inhibitor management in patients with haemophilia: implications of new treatment options},
   url = {https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-020-01511-8},
   volume = {15},
   year = {2020}
}

TY  - JOUR
ID  - 1681836
AU  - Hermans, C. - Giangrande, P. L. F. - O Mahony, B. - de Kleijn, P. - Bedford, M. - Batorova, A. - Blatný, Jan - Jansone, K.
PY  - 2020
TI  - European principles of inhibitor management in patients with haemophilia: implications of new treatment options
JF  - Orphanet Journal of Rare Diseases
VL  - 15
IS  - 1
SP  - 1-4
EP  - 1-4
PB  - England
SN  - 17501172
KW  - Haemophilia
KW  - Guidelines
KW  - Inhibitors
KW  - Factor VIII
KW  - Factor IX
KW  - Bypassing agents
KW  - Emicizumab
KW  - Immune tolerance
UR  - https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-020-01511-8
L2  - https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-020-01511-8
N2  - In light of the rapidly changing landscape of haemophilia treatment, the authors of the position paper on the “European Principles of Inhibitor Management” published in 2018 (Table 1) now provide an update on the major impact of novel therapies that bypass and/or substitute clotting factor VIII (FVIII) and IX (FIX) in the care of haemophilia patients with FVIII- or FIXneutralizing allo-inhibitory antibodies (inhibitors).
ER  -

HERMANS, C., P. L. F. GIANGRANDE, B. O MAHONY, P. DE KLEIJN, M. BEDFORD, A. BATOROVA, Jan BLATNÝ and K. JANSONE. European principles of inhibitor management in patients with haemophilia: implications of new treatment options. \textit{Orphanet Journal of Rare Diseases}. London: England, 2020, vol.~15, No~1, p.~1-4. ISSN~1750-1172. Available from: https://dx.doi.org/10.1186/s13023-020-01511-8.

Detailed Information on Publication Record